CNBX Pharmaceuticals Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
NV
Business Address
#3 BETHESDA METRO CENTER, BETHESDA, MD, 20814
Mailing Address
#3 BETHESDA METRO CENTER, BETHESDA, MD, 20814
Phone
877-424-2429
Fiscal Year End
0831
EIN
203373669
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 5, 2026 | View on SEC |
| 10-Q Quarterly financial report | January 14, 2026 | View on SEC |
| 10-K Annual financial report | December 1, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 10, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | August 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | July 14, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | May 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | April 14, 2025 | View on SEC |
Annual Reports
10-K
December 1, 2025
- CNBX Pharmaceuticals Inc. is categorized as a "smaller reporting company" and an "emerging growth company," reflecting its early growth stage.
- As of February 28, 2025, the company's public common stock had a market value of approximately $251,840, with shares priced at $0.0076 each.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.